EMA: First treatment against liver scarring caused by a type of ‘fatty liver disease’. Rezdiffra is indicated for patients with moderate to advanced scarring due to accumulation of fat
20 giugno 2025
Leggi
20 giugno 2025
Leggi
Rosenstock J, Bailey TS, Connery L, et al.
N Engl J Med. Pub. online 22 Jun 2025.
Leggi
Reichman TW, Markmann JF, Odorico J, et al.
N Engl J Med. Pub. online 20 Jun 2025.
Leggi
Gilbert O, Gulati M, Gluckman TJ, et al.
J Am Coll Cardiol. Pub. online 16 Jun 2025.
Leggi
Deng Y, Tam CHT, Yang A, et al.
Diabetologia. Pub. online 17 Jun 2025.
Leggi
Saeed A, Mulukutla SR, Thoma F, et al.
Ann Intern Med. Pub. online 17 Jun 2025.
Leggi
Boddu SK, Giannini C, Marcovecchio ML
Diabetologia. Pub. online 17 Jun 2025.
Leggi
Adams RN, Athinarayanan SJ, Zoller AR, et al.
Diabetes Obes Metab. Pub. online 16 Jun 2025.
Leggi
Pilla SJ, Yeh HC, Mitchell CM, et al.
JAMA Intern Med. 2025:e251580.
Leggi
Phillips SM, Spiga F, Moore TH, et al.
Cochrane Database Syst Rev. 2025;6:CD015326.
Leggi